Monocl appoints new Chairman

GÖTEBORG, SWEDEN, 1 October, 2013. Monocl AB, a leading Life Science Intelligence company, today announces the appointment of Greg Batcheller as its new Chairman. Greg Batcheller is a senior Life Science executive with multiple Chair positions in public pharma companies and has a track record as founder and operative manager of several successful startup companies.

Gregory Batcheller brings a strong track record from his previous positions in the Life Science industry as executive decision maker, company founder and commercial lawyer. He is currently the Chairman of public companies NeuroVive Pharmaceutical and A1M Pharma, and is involved with a number of other companies including Xintela and AcuCort. Greg is an active investor and active partner in P.U.L.S., and was for 7 years a key member of the management team that developed and successfully exited the Plenadren product to Viropharma Inc in 2011. Greg is an accomplished dealmaker and has successfully negotiated several international licensing and M&A deals in Europe, US and China. Greg has two law degrees from the University of Toronto, Canada, and Lund University, Sweden, and a B.Sc. from the London School of Economics.

“The decision to ask Greg to join the board of directors as Chairman was easy. Greg brings valuable insights both as Life Science executive and investor, which we will capture to refine our Life Science Intelligence platform. In addition, he provides an excellent customer perspective to our consultancy service offerings and software development process“, stated Björn Carlsson and Tobias Thornblad, founders of Monocl.

Greg Batcheller joins the company in an exciting phase of intense development and expansion. Recently, Monocl announced the appointment of Ann Gidner as the company’s new CEO and the opening of its second office at Medicon Village in Lund. During 2013, Monocl has established long-term collaborations and key accounts with public and private pharma, biotech and medical device clients. Monocl has also recruited key software development expertise to improve the current service offerings and to enable novel, groundbreaking business development products. In addition, Monocl was selected as one of the most innovative young growth companies by VINNOVA, the Swedish Governmental Agency for Innovation Systems, who has also chosen to support Monocl’s software development with state-funding of an approximate total amount of close to US$300 000. Monocl will beta test its software platform in exclusive pilot groups during 2014.

About Monocl

Monocl is a Life Science strategy consultancy firm improving decision-making for company executives. We partner with our clients to deliver tailored Life Science Intelligence through management tools and software products. Whether it is competitive positioning, business analysis or strategy execution, we empower our clients with a competitive edge and capabilities for lasting business impact.

Media contact

Ann Gidner, CEO, Monocl AB
ann.gidner@monocl.com
+46 769 412 412